Journal Scans
Cetuximab Plus Oxaliplatin/Leucovorin/5-Fluorouracil in First-Line Metastatic Gastric Cancer: A Phase II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Cetuximab, Oxaliplatin, LV, and 5-FU in Gastric Cancer
F Lordick, B Luber, S Lorenzen, S Hegewisch-Becker, G Folprecht, E Wöll, T Decker, E Endlicher, N Röthling, T Schuster, G Keller, F Fend, C Peschel
20100012
2010 Jan 12
Br J Cancer
Cetuximab Plus Oxaliplatin/Leucovorin/5-Fluorouracil in First-Line Metastatic Gastric Cancer: A Phase II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Br J Cancer. 2010 Jan 12;2010(102):500-505, F Lordick, B Luber, S Lorenzen, S Hegewisch-Becker, G Folprecht, E Wöll, T Decker, E Endlicher, N Röthling, T Schuster, G Keller, F Fend, C Peschel
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed the activity of cetuximab and chemotherapy in advanced gastric cancer. Methods: Patients with previously untreated, metastatic, gastric cancer received cetuximab 400 mg m−2 at first infusion followed by weekly infusions of 250 mg m−2 combined with FUFOX (oxaliplatin 50 mg m−2, 5-FU 2000 mg m−2, and DL-folinic acid 200 mg m−2 d1, 8, 15 and 22 qd36). The primary endpoint was tumour response.Results:...
